Recently, the suggestion to use 6-thioguanine (6-TG) as an alternative thiopurine in patients with inflammatory bowel disease (IBD) has been discarded due to reports about possible (hepato) toxicity. During meetings arranged in Vienna and Prague in 2004, European experts applying 6-TG further on in IBD patients presented data on safety and efficacy of 6-TG. After thorough evaluation of its risk-benefit ratio, the group consented that 6-TG may still be considered as a rescue drug in stringently defined indications in IBD, albeit restricted to a clinical research setting. As a potential indication for administering 6-TG, we delineated the requirement for maintenance therapy as well as intolerance and/or resistance to aminosalicylates, azathioprine, 6-mercaptopurine, methotrexate and infliximab. Furthermore, indications are preferred in which surgery is thought to be inappropriate. The standard 6-TG dosage should not exceed 25 mg daily. Routine laboratory controls are mandatory in short intervals. Liver biopsies should be performed after 6–12 months, three years and then three-yearly accompanied by gastroduodenoscopy, to monitor for potential hepatotoxicity, including nodular regenerative hyperplasia (NRH) and veno-occlusive disease (VOD). Treatment with 6-TG must be discontinued in case of overt or histologically proven hepatotoxicity.

Carter MJ, Lobo AJ, Travis SP: Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(suppl 5):V1–V16.
Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004;126:402–413.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–1549.
Rutgeerts P, Van Assche G, Vermeire S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593–1610.
Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR: Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis 2005;37:282–297.
Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi PG: Randomised, controlled trial, of azathioprine and 5-aminosalicylic acid for treatment of steroid-dependent ulcerative colitis. Gut 2005; in press.
Rutgeerts P, Feagan BG, Olson A, Johanns J, Travers S, Present D, Sands BE, Sandborn W, Olson A: A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: Act I Trial. Gastroenterology 2005;128:A35–A36.
Sandborn W, Rachmilewitz D, Hanauer SB, Lichtensten GR, de Villiers WJ, Olson A, Johanns J, Travers S, Colombel JF: Infliximab induction and maintenance therapy for ulcerative colitis: the Act 2 Trial. Gastroenterology 2005;128:A36.
de Jong D, Mulder CJ, van Sorge AA: Why measure thiopurine methyltransferase activity? Direct administration of 6-thioguanine might be the alternative for 6-mercaptopurine or azathioprine. Gut 2001;49:874.
Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF: 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003;125:298–303.
Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV: Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001;61:5810–5816.
Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF: CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133–1145.
Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, Zanger UM, Schwab M: Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004;14:407–417.
Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, Soule JC, Modigliani R, Touze Y, Catala P, Libersa C, Broly F: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025–1030.
McBride KL, Gilchrist GS, Smithson WA, Weinshilboum RM, Szumlanski CL: Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency. J Pediatr Hematol Oncol 2000;22:441–445.
Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705–713.
Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, Lewis CM, Shobowale-Bakre e, Escuredo E, Fairbanks LD, Sanderson JD: Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004;14:181–187.
Gearry RB, Roberts RL, Barclay ML, Kennedy MA: Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 2004;14:779–781.
van Dieren JM, van Vuuren AJ, Kusters JG, Nieuwenhuis EE, Kuipers EJ, van der Woude CJ: ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut 2005;54:1664.
Bean, RHD: Treatment of ulcerative colitis with antimetabolites. Br Med J 1966;1:1081–1084.
Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA: An open-label pilot study using thioguanine as a therapeutic alternative in Crohn’s disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001;7:181–189.
Herrlinger KR, Kreisel W, Schwab M, Schoelmerich J, Fleig WE, Ruhl A, Reinshagen M, Deibert P, Fellermann K, Greinwald R, Stange EF: 6-thioguanine–efficacy and safety in chronic active Crohn’s disease. Aliment Pharmacol Ther 2003;17:503–508.
Herrlinger KR, Deibert P, Schwab M, Kreisel W, Fischer C, Fellermann K, Stange EF: Remission maintenance by tioguanine in chronic active Crohn’s disease. Aliment Pharmacol Ther 2003;17:1459–1464.
Bonaz B, Boitard J, Marteau P, Lemann M, Coffin B, Flourie B, Belaiche J, Cadiot G, Metman EH, Cortot A, Colombel JF: Tioguanine in patients with Crohn’s disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2003;18:401–408.
Derijks LJ, de Jong DJ, Gilissen LP, Engels LG, Hooymans PM, Jansen JB, Mulder CJ: 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 2003;15:63–67.
Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA: Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003;98:1058–1063.
Teml A, Schwab M, Harrer M, Miehsler W, Schaeffeler E, Dejaco C, Mantl M, Schneider B, Vogelsang H, Reinisch W: A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis. Scand J Gastroenterol 2005;40:1205–1213.
Teml A, Dejaco C, Miehsler W, Harrer M, Vogelsang H, Reinisch W: Long-term efficacy of 6-thioguanine in patients with inflammatory bowel disease. Gut 2005;53(suppl VI):A229.
de Boer NK, Derijks LJ, Gilissen LP, Hommes DW, Engels LG, de Boer SY, den Hartog G, Hooymans PM, Makelburg AB, Westerveld BD, Naber AH, Mulder CJ, de Jong DJ: On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J Gastroenterol 2005;11:5540–5544.
Teml A, Hommes D, Almer S, Lukas M, Feichtenschlager T, Florin T, Ochsenkuhn T, Petritsch W, Bokemeyer B, Kreisel W, Herrlinger K, Knoflach P, Roblin X, Klugmann T, Herfarth H, Schwab M, Perdarnig M, Reinisch W: The 6-thioguanine (6-TG) online survey platform: an international, multi-centric approach to summarize clinical data collected during the use of 6-TG in patients with inflammatory bowel disease (IBD). Gut 2005;54(suppl VII):A44.
Buffet C, Cantarovitch M, Pelletier G, Fabre M, Martin E, Charpentier B, Etienne JP, Fries D: Three cases of nodular regenerative hyperplasia of the liver following renal transplantation. Nephrol Dial Transplant 1988;3:327–330.
Russmann S, Zimmermann A, Krahenbuhl S, Kern B, Reichen J: Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol 2001;13:287–290.
Naber AH, Van Haelst U, Yap SH: Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients. J Hepatol 1991;12:94–99.
Daniel F, Cadranel JF, Seksik P, Cazier A, Duong Van Huyen JP, Ziol M, Coutarel P, Loison P, Jian R, Marteau P: Azathioprine induced nodular regenerative hyperplasia in IBD patients. Gastroenterol Clin Biol 2005;29:600–603.
Jones MC, Best PV, Catto GR: Is nodular regenerative hyperplasia of the liver associated with azathioprine therapy after renal transplantation? Nephrol Dial Transplant 1988;3:331–333.
Haboubi NY, Ali HH, Whitwell HL, Ackrill P: Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations. Am J Gastroenterol 1988;83:256–261.
Fonseca V, Havard CW: Portal hypertension secondary to azathioprine in myasthenia gravis. Postgrad Med J 1988;64:950–952.
Gane E, Portmann B, Saxena R, Wong P, Ramage J, Williams R: Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 1994;20:88–94.
Shastri S, Dubinsky MC, Fred PF, Vasiliauskas EA, Geller SA: Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy. Arch Pathol Lab Med 2004;128:49–53.
Seiderer J, Zech CJ, Reinisch W, Lukas M, Diebold J, Wrba F, Teml A, Chalupna P, Stritesky J, Schoenberg SO, Schima W, Goke B, Ochsenkuhn T: A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol 2005;43:303–309.
Ferlitsch A, Teml A, Reinisch W, Peck-Radosavljevic M, Wrba F, Ulbrich G, Vogelsang H: 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Gut 2005;54(suppl VII):A45.
de Boer NK, Mulder CJ, van Bodegraven AA: Nodular regenerative hyperplasia and thiopurines: the case for level-dependent toxicity. Liver Transpl 2005;11:1300–1301.
Katzka DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD: Azathioprine and hepatic venocclusive disease in renal transplant patients. Gastroenterology 1986;90:446–454.
De Bruyne R, Portmann B, Samyn M, Bansal S, Knisely A, Mieli-Vergani G, Dhawan A: Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia. J Hepatol 2005. Epub ahead of print.
Herrlinger KR, Fellermann K, Fischer C, Kreisel W, Deibert P, Schoelmerich J, Fleig WE, Ruhl A, Reinshagen M, Greinwald R, Stange EF, Schwab M: Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn’s disease. Aliment Pharmacol Ther 2004;19:1269–1276.
Lilleyman JS, Hill AS, Anderton KJ: Consequences of acute myelogenous leukemia in early pregnancy. Cancer 1977;40:1300–1303.
Artlich A, Moller J, Tschakaloff A, Schwinger E, Kruse K, Gortner L: Teratogenic effects in a case of maternal treatment for acute myelocytic leukaemia: neonatal and infantile course. Eur J Pediatr 1994;153:488–491.
De Boer N, van Elburg R, Wilhelm A, Remmink A, van Vugt J, Mulder C, van Bodegraven A: 6-Thioguanine for Crohn’s disease during pregnancy: thiopurine metabolite measurements in both mother and child. Scand J Gastroenterol 2005;40:1374–1377.
You do not currently have access to this content.